(Q40395107)

English

Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway

scientific article published on September 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Yao Q

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Nishiuchi R

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Kitamura T

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Kersey JH

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

publication date

1 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1605-1612

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403881

0 references

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

FLT3: ITDoes matter in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Hsp90 inhibitors as novel cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Killing the messenger: short RNAs that silence gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

21 January 2018

Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403881

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403881

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40395107&oldid=2125513583"